TriangleRABBIT (NCT06814496)
RABBIT trial for Relapsed/Refractory DLL3-Expressing Tumors (NCT06814496). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with relapsed or refractory tumors that express DLL3, such as small cell lung cancer and other small cell or neuroendocrine cancers.
The idea: combine radiation with tarlatamab, a bispecific T-cell engager given by infusion. Standard radiation is given during tarlatamab treatment, first to sites outside the brain, and later possibly to the brain.
This phase 1 and 2 study plans 30 patients and looks at dose limiting side effects. At the University of Arizona, Charles Hsu and Ricklie Julian lead it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.